Comparison · NCT04526665-sae
Elafibranor 80 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Elafibranor 80 mg vs Placebo: serious adverse events. Trial comparisons, record NCT04526665-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04526665-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.102 | 0.0578 | 0.173 | wilson | |
| Risk in group 2 | 0.132 | 0.0655 | 0.248 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0302 | -0.155 | 0.0674 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.771 | 0.317 | 1.88 | log | |
| Odds ratio, group 1 over group 2 | 0.745 | 0.271 | 2.05 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Elafibranor 80 mg than on Placebo | 33.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Elafibranor 80 mg | Participants received elafibranor 80 mg orally once daily before breakfast during the DB period (maximum observed exposure= 104 weeks). | 11 | 108 | EG000 |
| Group 2 | Placebo | Participants received placebo matched to elafibranor orally once daily before breakfast during the DB period (maximum observed exposure= 106 weeks). | 7 | 53 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Treatment-emergent adverse events (TEAEs) were reported from the start of study treatment administration (Day 1) up to DCO date of 01 June 2023, approximately 980 days.
Source ClinicalTrials.gov
Trial
- Title
- Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
- NCT number
- NCT04526665
- Phases
- PHASE3
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Elafibranor 80mg, Placebo
- Lead sponsor
- Ipsen
- Results first posted
- 2024-09-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04526665?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04526665-sae